Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Share Class Description:
TGTX: Ordinary SharesDescription
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.96 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.69 | |||||
| Debt-to-EBITDA | 4.25 | |||||
| Interest Coverage | 1.64 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.16 | |||||
| Beneish M-Score | 71.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1063 | |||||
| 3-Year FCF Growth Rate | 51.5 | |||||
| 3-Year Book Growth Rate | -34 | |||||
| Future 3-5Y Total Revenue Growth Rate | 36.31 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.36 | |||||
| 9-Day RSI | 33.44 | |||||
| 14-Day RSI | 37.35 | |||||
| 6-1 Month Momentum % | 120.03 | |||||
| 12-1 Month Momentum % | -28.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.92 | |||||
| Quick Ratio | 5.18 | |||||
| Cash Ratio | 4.05 | |||||
| Days Inventory | 844.83 | |||||
| Days Sales Outstanding | 45.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.5 | |||||
| Shareholder Yield % | -0.16 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.95 | |||||
| Operating Margin % | 8.83 | |||||
| Net Margin % | 5.42 | |||||
| FCF Margin % | -13.44 | |||||
| ROE % | 14.03 | |||||
| ROA % | 4.98 | |||||
| ROIC % | 34.38 | |||||
| ROC (Joel Greenblatt) % | 63.79 | |||||
| ROCE % | 13.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1399 | |||||
| Forward PE Ratio | 140.6 | |||||
| PE Ratio without NRI | 1399 | |||||
| PS Ratio | 9.23 | |||||
| PB Ratio | 13.2 | |||||
| Price-to-Tangible-Book | 13.26 | |||||
| EV-to-EBIT | 79.98 | |||||
| EV-to-EBITDA | 78.68 | |||||
| EV-to-Revenue | 8.79 | |||||
| EV-to-Forward-Revenue | 8.46 | |||||
| EV-to-FCF | -65.38 | |||||
| Price-to-Graham-Number | 9.58 | |||||
| Price-to-Net-Current-Asset-Value | 14.28 | |||||
| Price-to-Net-Cash | 43.72 | |||||
| Earnings Yield (Greenblatt) % | 1.25 | |||||
| FCF Yield % | -1.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TG Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 233.663 | ||
| EPS (TTM) ($) | 0.01 | ||
| Beta | 2.16 | ||
| Volatility % | 118.35 | ||
| 14-Day RSI | 37.35 | ||
| 14-Day ATR ($) | 0.646125 | ||
| 20-Day SMA ($) | 14.7425 | ||
| 12-1 Month Momentum % | -28.96 | ||
| 52-Week Range ($) | 6.46 - 35.67 | ||
| Shares Outstanding (Mil) | 154.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TG Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TG Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TG Therapeutics Inc Frequently Asked Questions
What is TG Therapeutics Inc(TGTX)'s stock price today?
The current price of TGTX is $13.99. The 52 week high of TGTX is $35.67 and 52 week low is $6.46.
When is next earnings date of TG Therapeutics Inc(TGTX)?
The next earnings date of TG Therapeutics Inc(TGTX) is 2024-05-01 Est..
Does TG Therapeutics Inc(TGTX) pay dividends? If so, how much?
TG Therapeutics Inc(TGTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers